Download PDF
CC BY-NC-ND 4.0 · Geburtshilfe Frauenheilkd 2021; 81(10): 1145-1153
DOI: 10.1055/a-1545-4279
GebFra Science
Review/Übersicht

2020 WHO Classification of Female Genital Tumors

Article in several languages: English | deutsch
Anne Kathrin Höhn
1   Arbeitsgruppe Mamma, Gynäko- & Perinatalpathologie, Institut für Pathologie, Universitätsklinikum Leipzig AöR, Leipzig
,
Christine E. Brambs
2   Frauenklinik, Kantonsspital, Luzern, Schweiz
,
Grit Gesine Ruth Hiller
1   Arbeitsgruppe Mamma, Gynäko- & Perinatalpathologie, Institut für Pathologie, Universitätsklinikum Leipzig AöR, Leipzig
,
Doris May
3   Pathologisches Institut der Ludwig-Maximilians-Universität München, München
,
Elisa Schmoeckel
3   Pathologisches Institut der Ludwig-Maximilians-Universität München, München
,
Lars-Christian Horn
1   Arbeitsgruppe Mamma, Gynäko- & Perinatalpathologie, Institut für Pathologie, Universitätsklinikum Leipzig AöR, Leipzig
› Author Affiliations
› Further Information
Also available at
   Permissions and Reprints

Abstract

The 2020 WHO classification is focused on the distinction between HPV-associated and HPV-independent squamous cell carcinoma of the lower female genital organs. Differentiating according to HPV association does not replace the process of grading; however, the WHO classification does not recommend any specific grading system. VIN are also differentiated according to whether they are HPV(p16)-associated. HPV-independent adenocarcinoma (AC) of the cervix uteri has an unfavorable prognosis. Immunohistochemical p16 expression is considered to be a surrogate marker for HPV association. HPV-associated AC of the cervix uteri is determined using the prognostically relevant Silva pattern.

Key words

p16 immunohistochemistry - HPV - Silva pattern


Publication History

Received: 16 April 2021

Accepted after revision: 05 July 2021

Article published online:
06 October 2021

© 2021. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commecial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • References/Literatur

  • 1 Lokuhetty D, White VA, Watanabe R. Female genital Tumours. 5th ed. Lyon: Internal Agency for Research on Cancer (IARC); 2020
    Google Scholar
  • 2 Singh N, Gilks CB. Vulval squamous cell carcinoma and its precursors. Histopathology 2020; 76: 128-138
    CrossrefPubMedGoogle Scholar
  • 3 Watkins JC. Human Papillomavirus-Independent Squamous Lesions of the Vulva. Surg Pathol Clin 2019; 12: 249-261
    CrossrefPubMedGoogle Scholar
  • 4 Heller DS, Day T, Allbritton JI. et al. Diagnostic Criteria for Differentiated Vulvar Intraepithelial Neoplasia and Vulvar Aberrant Maturation. J Low Genit Tract Dis 2021; 25: 57-70
    CrossrefPubMedGoogle Scholar
  • 5 Barlow EL, Lambie N, Donoghoe MW. et al. The Clinical Relevance of p16 and p53 Status in Patients with Squamous Cell Carcinoma of the Vulva. J Oncol 2020; 2020: 3739075
    CrossrefPubMedGoogle Scholar
  • 6 Sand FL, Nielsen DMB, Frederiksen MH. et al. The prognostic value of p16 and p53 expression for survival after vulvar cancer: A systematic review and meta-analysis. Gynecol Oncol 2019; 152: 208-217
    CrossrefPubMedGoogle Scholar
  • 7 Tessier-Cloutier B, Pors J, Thompson E. et al. Molecular characterization of invasive and in situ squamous neoplasia of the vulva and implications for morphologic diagnosis and outcome. Mod Pathol 2021; 34: 508-518
    CrossrefPubMedGoogle Scholar
  • 8 Cheng AS, Karnezis AN, Jordan S. et al. p16 Immunostaining Allows for Accurate Subclassification of Vulvar Squamous Cell Carcinoma Into HPV-Associated and HPV-Independent Cases. Int J Gynecol Pathol 2016; 35: 385-393
    CrossrefPubMedGoogle Scholar
  • 9 Santos M, Landolfi S, Olivella A. et al. p16 overexpression identifies HPV-positive vulvar squamous cell carcinomas. Am J Surg Pathol 2006; 30: 1347-1356
    CrossrefPubMedGoogle Scholar
  • 10 Nooij LS, Ter Haar NT, Ruano D. et al. Genomic Characterization of Vulvar (Pre)cancers Identifies Distinct Molecular Subtypes with Prognostic Significance. Clin Cancer Res 2017; 23: 6781-6789
    CrossrefPubMedGoogle Scholar
  • 11 Woelber L, Prieske K, Eulenburg C. et al. p53 and p16 expression profiles in vulvar cancer: a translational analysis by the Arbeitsgemeinschaft Gynäkologische Onkologie Chemo and Radiotherapy in Epithelial Vulvar Cancer study group. Am J Obstet Gynecol 2021; 224: 595.e1-595.e11
    CrossrefPubMedGoogle Scholar
  • 12 Darragh TM, Colgan TJ, Thomas Cox J. et al. The Lower Anogenital Squamous Terminology Standardization project for HPV-associated lesions: background and consensus recommendations from the College of American Pathologists and the American Society for Colposcopy and Cervical Pathology. Int J Gynecol Pathol 2013; 32: 76-115
    CrossrefPubMedGoogle Scholar
  • 13 Dasgupta S, Ewing-Graham PC, Swagemakers SMA. et al. Precursor lesions of vulvar squamous cell carcinoma – histology and biomarkers: A systematic review. Crit Rev Oncol Hematol 2020; 147: 102866
    CrossrefPubMedGoogle Scholar
  • 14 Tessier-Cloutier B, Kortekaas KE, Thompson E. et al. Major p53 immunohistochemical patterns in in situ and invasive squamous cell carcinomas of the vulva and correlation with TP53 mutation status. Mod Pathol 2020; 33: 1595-1605
    CrossrefPubMedGoogle Scholar
  • 15 Yap ML, Allo G, Cuartero J. et al. Prognostic Significance of Human Papilloma Virus and p16 Expression in Patients with Vulvar Squamous Cell Carcinoma who Received Radiotherapy. Clin Oncol (R Coll Radiol) 2018; 30: 254-261
    CrossrefPubMedGoogle Scholar
  • 16 Lee LJ, Howitt B, Catalano P. et al. Prognostic importance of human papillomavirus (HPV) and p16 positivity in squamous cell carcinoma of the vulva treated with radiotherapy. Gynecol Oncol 2016; 142: 293-298
    CrossrefPubMedGoogle Scholar
  • 17 Proctor L, Hoang L, Moore J. et al. Association of human papilloma virus status and response to radiotherapy in vulvar squamous cell carcinoma. Int J Gynecol Cancer 2020; 30: 100-106
    CrossrefPubMedGoogle Scholar
  • 18 Allo G, Yap ML, Cuartero J. et al. HPV-independent Vulvar Squamous Cell Carcinoma is Associated With Significantly Worse Prognosis Compared With HPV-associated Tumors. Int J Gynecol Pathol 2020; 39: 391-399
    CrossrefPubMedGoogle Scholar
  • 19 Rasmussen CL, Sand FL, Hoffmann Frederiksen M. et al. Does HPV status influence survival after vulvar cancer?. Int J Cancer 2018; 142: 1158-1165
    CrossrefPubMedGoogle Scholar
  • 20 McAlpine JN, Leung SCY, Cheng A. et al. Human papillomavirus (HPV)-independent vulvar squamous cell carcinoma has a worse prognosis than HPV-associated disease: a retrospective cohort study. Histopathology 2017; 71: 238-246
    CrossrefPubMedGoogle Scholar
  • 21 Angelico G, Santoro A, Inzani F. et al. Hormonal Environment and HER2 Status in Extra-Mammary Pagetʼs Disease (eMPD): A Systematic Literature Review and Meta-Analysis with Clinical Considerations. Diagnostics (Basel) 2020; 10: 1040
    CrossrefPubMedGoogle Scholar
  • 22 Hellman K, Lindquist D, Ranhem C. et al. Human papillomavirus, p16(INK4A), and Ki-67 in relation to clinicopathological variables and survival in primary carcinoma of the vagina. Br J Cancer 2014; 110: 1561-1570
    CrossrefPubMedGoogle Scholar
  • 23 Höckel M, Horn L-C, Illig R. et al. Ontogenetic anatomy of the distal vagina: relevance for local tumor spread and implications for cancer surgery. Gynecol Oncol 2011; 122: 313-318
    CrossrefPubMedGoogle Scholar
  • 24 Horn L-C, Höhn AK, Hampl M. et al. S2k-Leitlinie Diagnostik und Therapie des Vaginalkarzinoms und seiner Vorstufen – Anforderungen an die Pathologie. Der Pathologe 2021; 42: 116-124
    CrossrefPubMedGoogle Scholar
  • 25 de Sanjosé S, Serrano B, Tous S. et al. RIS HPV TT, VVAP and Head and Neck study groups. Burden of Human Papillomavirus (HPV)-Related Cancers Attributable to HPVs 6/11/16/18/31/33/45/52 and 58. JNCI Cancer Spectr 2019; 2: pky045
    CrossrefPubMedGoogle Scholar
  • 26 Li N, Franceschi S, Howell-Jones R. et al. Human papillomavirus type distribution in 30,848 invasive cervical cancers worldwide: Variation by geographical region, histological type and year of publication. Int J Cancer 2011; 128: 927-935
    CrossrefPubMedGoogle Scholar
  • 27 Casey S, Harley I, Jamison J. et al. A rare case of HPV-negative cervical squamous cell carcinoma. Int J Gynecol Pathol 2015; 34: 208-212
    CrossrefPubMedGoogle Scholar
  • 28 Hodgson A, Olkhov-Mitsel E, Howitt BE. et al. International Endocervical Adenocarcinoma Criteria and Classification (IECC): correlation with adverse clinicopathological features and patient outcome. J Clin Pathol 2019; 72: 347-353
    CrossrefPubMedGoogle Scholar
  • 29 Stolnicu S, Hoang L, Chiu D. et al. Clinical Outcomes of HPV-associated and Unassociated Endocervical Adenocarcinomas Categorized by the International Endocervical Adenocarcinoma Criteria and Classification (IECC). Am J Surg Pathol 2019; 43: 466-474
    CrossrefPubMedGoogle Scholar
  • 30 Nicolás I, Saco A, Barnadas E. et al. Prognostic implications of genotyping and p16 immunostaining in HPV-positive tumors of the uterine cervix. Mod Pathol 2020; 33: 128-137
    CrossrefPubMedGoogle Scholar
  • 31 Stolnicu S, Barsan I, Hoang L. et al. International Endocervical Adenocarcinoma Criteria and Classification (IECC): A New Pathogenetic Classification for Invasive Adenocarcinomas of the Endocervix. Am J Surg Pathol 2018; 42: 214-226
    CrossrefPubMedGoogle Scholar
  • 32 AWMF. S3-Leitlinie zur Diagnostik, Therapie und Nachsorge der Patientin mit Zervixkarzinom, 2021. Accessed January 26, 2021 at: https://www.awmf.org/leitlinien/detail/ll/032-033OL.html
    PubMedGoogle Scholar
  • 33 Nuovo GJ, Plaia TW, Belinsky SA. et al. In situ detection of the hypermethylation-induced inactivation of the p16 gene as an early event in oncogenesis. Proc Natl Acad Sci U S A 1999; 96: 12754-12759
    CrossrefPubMedGoogle Scholar
  • 34 Shain AF, Kwok S, Folkins AK. et al. Utility of p16 Immunohistochemistry in Evaluating Negative Cervical Biopsies Following High-risk Pap Test Results. Am J Surg Pathol 2018; 42: 69-75
    CrossrefPubMedGoogle Scholar
  • 35 Shain AF, Wilbur DC, Stoler MH. et al. Test Characteristics of Specific p16 Clones in the Detection of High-grade Squamous Intraepithelial Lesions (HSIL). Int J Gynecol Pathol 2018; 37: 82-87
    CrossrefPubMedGoogle Scholar
  • 36 Nuovo AJ, Garofalo M, Mikhail A. et al. The effect of aging of formalin-fixed paraffin-embedded tissues on the in situ hybridization and immunohistochemistry signals in cervical lesions. Diagn Mol Pathol 2013; 22: 164-173
    CrossrefPubMedGoogle Scholar
  • 37 Carleton C, Hoang L, Sah S. et al. A Detailed Immunohistochemical Analysis of a Large Series of Cervical and Vaginal Gastric-type Adenocarcinomas. Am J Surg Pathol 2016; 40: 636-644
    CrossrefPubMedGoogle Scholar
  • 38 Parra-Herran C, Taljaard M, Djordjevic B. et al. Pattern-based classification of invasive endocervical adenocarcinoma, depth of invasion measurement and distinction from adenocarcinoma in situ: interobserver variation among gynecologic pathologists. Mod Pathol 2016; 29: 879-892
    CrossrefPubMedGoogle Scholar
  • 39 Ip PP. Benign endometrial proliferations mimicking malignancies: a review of problematic entities in small biopsy specimens. Virchows Arch 2018; 472: 907-917
    CrossrefPubMedGoogle Scholar
  • 40 Howitt BE, Quade BJ, Nucci MR. Uterine polyps with features overlapping with those of Müllerian adenosarcoma: a clinicopathologic analysis of 29 cases emphasizing their likely benign nature. Am J Surg Pathol 2015; 39: 116-126
    CrossrefPubMedGoogle Scholar
  • 41 McCluggage WG. A practical approach to the diagnosis of mixed epithelial and mesenchymal tumours of the uterus. Mod Pathol 2016; 29 (Suppl. 01) S78-S91
    CrossrefPubMedGoogle Scholar
  • 42 Knopp S, Bjørge T, Nesland JM. et al. p16INK4a and p21Waf1/Cip1 expression correlates with clinical outcome in vulvar carcinomas. Gynecol Oncol 2004; 95: 37-45
    CrossrefPubMedGoogle Scholar
  • 43 Roma AA, Mistretta T-A, Diaz De Vivar A. et al. New pattern-based personalized risk stratification system for endocervical adenocarcinoma with important clinical implications and surgical outcome. Gynecol Oncol 2016; 141: 36-42
    CrossrefPubMedGoogle Scholar
  • 44 Höckel M, Trott S, Dornhöfer N. et al. Vulvar field resection based on ontogenetic cancer field theory for surgical treatment of vulvar carcinoma: a single-centre, single-group, prospective trial. Lancet Oncol 2018; 19: 537-548
    CrossrefPubMedGoogle Scholar